Active Clinical Trials for Prostate Cancer

This page lists many active clinical trials (protocols) at Fox Chase Cancer Center for Prostate cancer. In addition to the title, some studies below have brief summaries.

Clinical trials, or protocols, are research studies conducted with people who volunteer to take part. You benefit by having access to new cancer treatments and options not otherwise available, in addition to the excellent care offered at Fox Chase.

For more information on clinical trials at Fox Chase Cancer Center, or to find a study, call 1-888 FOX CHASE (1-888-369-2427).
Open DateTrial NumberPrincipal InvestigatorTitle
11/19/1996IRB96091/96-091Elias Obeid Prostate Cancer Risk Assessment Program
10/28/201515-7002/15-7002Lori Goldstein Molecular Analysis for Therapy Choice (MATCH)
12/13/201717-1051/17-1051Anthony Olszanski A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
01/01/201815-8013/15-8013Suzanne Miller Improving Decision-Making for Low Health Literate Prostate Cancer Patients
05/01/201817-8009/17-8009Camille Ragin Cancer Genome Registry to Promote Health Equity Among Patients of African Ancestry
07/10/201817-8013/17-8013Linda Fleisher Mychoice: Testing an Interactive mHealth Tool to Enhance Communication and Informed Decision Making About Clinical Trial Participation in Cancer Patients
03/27/201918-8003/18-8003Michael Hall Patient Perceptions of Tumor Genomic Multi-Gene Panel Testing (MTGP) and the Management of Secondary Hereditary Results
05/13/201919-8005/19-8005Camille Ragin African Caribbean Cancer Consortium Prostate Cancer Advocacy and Survivorship Conference for Men of African Descent Focus Groups
11/11/201919-8014/19-8014Erin Tagai Decision Making for Medical Management of Low Risk Prostate Cancer: A Multilevel Qualitative Evaluation
11/13/201717-9042/17-9042Jeffrey Farma Impact of Enhanced Recovery After Surgery on Perioperative Outcomes Following Elective Complex Cancer Surgery
07/23/201818-8004/18-8004Alexander Kutikov Prospective Data Collection for Analysis Comparing Detection of Clinically Significant Prostate Cancer Using Us/Mri Fusion Targeted Biopsy With the Traditional Standard 12-core Template Biopsy
09/18/2003IRB03835/03-835Eric Horwitz Prospective Collection Of Characteristics And Outcome Of Patients Treated For Prostate Cancer At Fox Chase Cancer Center
02/13/202019-2015/19-2015Mark Hallman Phase 3 IGRT And SBRT Vs IGRT And Hypofractionated IMRT For Localized Intermediate Risk Prostate Cancer
07/10/201919-4001/19-4001Sanjeevani Arora Screen for Constitutional Genomic Instability and Environmental Effects in Patients at High-Risk for Cancer
05/17/201818-2007/18-2007Alvaro Pereira-Rico Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial
09/24/201818-1038/18-1038Anthony Olszanski An Open Label, Dose-Escalation, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-981 in Adult Patients With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019
04/01/201918-1045/18-1045Crystal Denlinger Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors
02/25/201918-8012/18-8012Alvaro Pereira-Rico GU-149 Observing Adherence to Oral Anticancer Therapies in Advanced Prostate and Breast Cancer Patients Treated at an Urban Hospital
10/29/201918-1076/18-1076Anthony Olszanski A Phase 1 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
08/12/201919-2008/19-2008Laura Levin Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer
06/24/202019-1044/19-1044Anthony Olszanski A Phase 1a/1b Dose-escalation Study of Intravenously Administered SB 11285 Alone and in Combination with Atezolizumab in Patients with Advanced Solid Tumors
07/13/202019-1043/19-1043Anthony Olszanski A Phase I Study of GNX102 in patients with Advanced Solid Tumors
07/31/202019-1054/19-1054Rishi Jain A Phase 1a/b Dose Finding Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy
04/24/202020-1007/20-1007Anthony Olszanski A Phase I, Open Label, Multiple-Ascending Dose Study To Investigate The Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 in Subjects with Metastatic or Locally Advanced Solid Tumors
07/30/202020-1009/20-1009Anthony Olszanski RT-90: A Phase I Dose Finding Study Of Low-dose Radiation With Sensitization Using 5-aminolevulinic Acid In Advanced Malignancies
01/13/201716-1043/16-1043Alexander Kutikov Reducing the Effects of Active Surveillance Stress, Uncertainty and Rumination thru Engagement in Mindfulness Education